{"analyses":[{"ciLowerLimit":"0.56","ciNumSides":"TWO_SIDED","ciPctValue":"96.4","ciUpperLimit":"0.86","estimateComment":"Stratified Cox proportional hazard model. Hazard Ratio is Nivolumab over Placebo.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0003","paramType":"Hazard Ratio (HR)","paramValue":"0.69","statisticalMethod":"Stratified log-rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.62","upperLimit":"34.00","value":"22.41"},{"groupId":"OG001","lowerLimit":"8.34","upperLimit":"14.32","value":"11.04"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"532"},{"groupId":"OG001","value":"262"}],"units":"Participants"}],"description":"Disease-free survival is defined as the time between randomization date and first date of recurrence or death, whichever occurs first.\n\nRecurrence is defined as the appearance of one or more new lesions, which can be local, regional, or distant in location from the primary resected site ( assessed by imaging or pathology). All deaths without prior recurrence are considered as DFS events. For participants who remained alive and without recurrence, DFS was censured on the date of last evaluable disease assessment","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 240 mg Q2W for 8 cycles (16 weeks) followed by Nivolumab 480 mg Q4W for 9 cycles.","id":"OG000","title":"Nivolumab"},{"description":"Placebo IV Q2W for 8 cycles (16 weeks) followed by Placebo IV Q4W for 9 cycles","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to the date of recurrence or death (up to approximately 46 months)","title":"Disease-free Survival (DFS)","type":"PRIMARY","unitOfMeasure":"Months"}